Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)

Annals of the Rheumatic Diseases

Volumn 73, Issue 7, 2014, Pages 1393-1396

  Meiners, P M ^a   Vissink, A ^a   Kroese, F G M ^a   Spijkervet, F K L ^a   Smitt Kamminga, N Sillevis ^a   Abdulahad, W H ^a   Bulthuis Kuiper, J ^a   Brouwer, E ^a   Arends, S ^a   Bootsma, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; IMMUNOGLOBULIN G; PREDNISONE; RHEUMATOID FACTOR;

ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INFUSION RELATED REACTION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SHORT FORM 36; SJOEGREN SYNDROME; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

DISEASE ACTIVITY; DMARDS (BIOLOGIC); OUTCOMES RESEARCH; SJØGREN'S SYNDROME; T CELLS;

ADULT; ANTIRHEUMATIC AGENTS; COHORT STUDIES; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84902290218     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204653     Document Type: Article

References (17)

1. Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012;8:399-411.
2. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Eng J Med 1996;335:1369-77. (Pubitemid 26360457)
3. Furst DE, Keystome EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72:2-34.
4. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
5. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjögren's syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010;69:1103-9.
6. Seror R, Ravaud P, Mariette X, et al. EULAR Sjögren's syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Ann Rheum Dis 2011;70:968-72.
7. Seror R, Mariette X, Bowman S, et al. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the european league against rheumatism Sjögren's syndrome disease activity index. Arthritis Care Res (Hoboken) 2010;62:551-8.
8. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis 2012;71:1297-302.
9. Seror R, Gottenberg JE, Devauchelle-Pensec V, et al. ESSDAI and ESSPRI: EULAR indexes for a complete picture of primary Sjögren's syndrome patients. Arthritis Care Res (Hoboken) 2013;65:1358-64.
10. Moerman RV, Arends S, Meiners PM, et al. EULAR Sjögren's syndrome disease activity index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis 2014;73:472-4.
11. Kalk WW, Vissink A, Stegenga B, et al. Sialometry and sialochemistry: A non-invasive approach for diagnosing Sjögren's syndrome. Ann Rheum Dis 2002;61:137-44. (Pubitemid 34098429)
12. Smets EM, Garssen B, Bonke B, et al. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
13. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 1992;30:473-83.
14. Kremer JM, Russell AS, Emery P, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011;70:1826-30.
15. Genovese MC, Schiff M, Luggen M, et al. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 2012;39:1546-54.
16. Adler S, Korner M, Forger F, et al. Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: A pilot study. Arthritis Care Res (Hoboken) 2013;65:1862-8.
17. Burlage FR, Pijpe J, Coppes RP, et al. Variability of flow rate when collecting stimulated human parotid saliva. Eu J Oral Sci 2005;113:386-90. (Pubitemid 41499755)